| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $8,593,094 ) |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 001 | 4 | NIH | 2/23/2026 | $54,775 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 000 | 5 | NIH | 12/18/2025 | $2,695,731 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 000 | 4 | NIH | 3/3/2026 | $578,941 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F31NS141239 | Role of meningeal lymphatic drainage in CSF1R-related leukoencephalopathy | 001 | 1 | NIH | 1/15/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F31NS141239 | Role of meningeal lymphatic drainage in CSF1R-related leukoencephalopathy | 000 | 1 | NIH | 1/15/2026 | $49,538 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F32NS146048 | Decoding and Targeting the Molecular Mechanisms of TRAF7/KLF4 Driver Mutations in Meningioma | 000 | 1 | NIH | 2/24/2026 | $80,020 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 3 | NIH | 1/16/2026 | $49,738 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 001 | 2 | NIH | 3/5/2026 | $113,854 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35NS137447 | Expanding insights into FTD disease mechanisms | 000 | 2 | NIH | 12/17/2025 | $1,024,684 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA288808 | Epigenetic Regulation of T Cell Metabolism and Immune Functions by Sirt6 | 000 | 2 | NIH | 12/30/2025 | $164,619 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA296671 | ECT2 Isoform Switch in Pancreatic Cancer. | 000 | 2 | NIH | 12/16/2025 | $164,619 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DK117910 | Mechanisms of Hereditary Pancreatitis | 000 | 7 | NIH | 2/25/2026 | $690,067 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA295558 | Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor | 000 | 2 | NIH | 12/18/2025 | $539,735 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA262393 | Targeted Prevention of Postpartum-Related Breast Cancer (PRBC) | 000 | 5 | NIH | 1/16/2026 | $380,600 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 001 | 4 | NIH | 2/24/2026 | $70,955 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 000 | 4 | NIH | 12/15/2025 | $638,607 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 001 | 5 | NIH | 2/23/2026 | $299,525 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 000 | 4 | NIH | 12/24/2025 | $492,975 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG072719 | Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model | 000 | 5 | NIH | 2/18/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K24AG053435 | Neuropathological changes underlying clinical heterogeneity in Alzheimer dise | 002 | 11 | NIH | 3/4/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K24AG053435 | Neuropathological changes underlying clinical heterogeneity in Alzheimer dise | 001 | 11 | NIH | 2/12/2026 | $140,341 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | UG3AI190113 | Antibiotic Allergy: Phenotypes, Endotypes, and Mechanisms | 001 | 2 | NIH | 1/29/2026 | $351,394 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 000 | 5 | NIH | 12/11/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 000 | 2 | NIH | 3/5/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 000 | 2 | NIH | 3/5/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AI184071 | Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial) | 001 | 3 | NIH | 2/17/2026 | $1,017,955 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 000 | 2 | NIH | 10/21/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS121125 | Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insight | 000 | 5 | NIH | 1/7/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 000 | 4 | NIH | 10/27/2025 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 000 | 5 | NIH | 1/6/2026 | $0 |
| | 2026 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG078615 | Discovery of apoE4 modulators for Alzheimer’s disease therapy | 000 | 4 | NIH | 3/4/2026 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HG013718 | Supporting Just-in-Time Consent for Prenatal Screening | 000 | 1 | NIH | 2/12/2026 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HG011461 | PaSAGE: PAtient Supported Approaches to Gene Editing | 000 | 3 | NIH | 1/7/2026 | -$403,379 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA237602 | Involution-based biomarkers of breast cancer risk | 000 | 5 | NIH | 11/21/2025 | -$36,497 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA255068 | PRSS1 Mutation and Pancreatic Cancer Tumorigenesis | 000 | 4 | NIH | 2/18/2026 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG065219 | Impact of T cells on the CNS during aging and Alzheimer’s disease | 002 | 5 | NIH | 2/11/2026 | $0 |
| | 2026 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG065219 | Impact of T cells on the CNS during aging and Alzheimer’s disease | 000 | 5 | NIH | 1/27/2026 | -$485,149 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS110085 | Mitochondrial Sirtuin 3 in Parkinson's disease | 000 | 5 | NIH | 1/30/2026 | -$12,569 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS110085 | Mitochondrial Sirtuin 3 in Parkinson's disease | 000 | 5 | NIH | 1/30/2026 | -$3,384 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA233790 | Therapeutic implication of CD38 in CLL | 000 | 5 | NIH | 1/14/2026 | -$64,216 |
| | 2026 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA229560 | Role of ICAM1 in development and progression of pancreatic cancer | 000 | 5 | NIH | 1/14/2026 | $0 |
| | 2026 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG046139 | A Systems Approach to Targeting Innate Immunity in AD | 000 | 10 | NIH | 3/2/2026 | -$385 |
| | 2026 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1NS123052 | C9orf72-mediated features, transcriptomic signatures, and translational studies for frontotemporal dementia and related disorders | 000 | 1 | NIH | 2/23/2026 | $0 |
| | 2026 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1AG076122 | Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementias | 000 | 1 | NIH | 1/23/2026 | -$304,220 |
| | 2026 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1AG076122 | Capturing the molecular complexity of tau pathology-associated proteomes involved in the etiology of Alzheimer's disease and related dementias | 000 | 1 | NIH | 1/23/2026 | $304,220 |
|
| Issue Date FY: 2025 ( Subtotal = $53,918,576 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 002 | 5 | NIH | 9/16/2025 | $32,250 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA258274 | Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapy | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG067763 | Molecular characterization of extracellular vesicles for the spread of misfolded tau protein | 001 | 5 | NIH | 6/13/2025 | $48,912 |
|
